India Pharma Outlook Team | Saturday, 23 May 2026
Venus Remedies has strengthened its footprint in the Gulf region after receiving Marketing Authorization from the Saudi Food and Drug Authority for Plerixafor, a specialty injectable used in stem cell transplantation procedures.
The SFDA authorization marks a significant milestone for Venus Remedies as it is the company’s first approval for Plerixafor in any global market.
The approval is also an important step in Venus Remedies’ long-term strategy to expand its specialty injectables business and reduce dependence on conventional high-volume injectable drug.
With this move, Venus Remedies strengthens GCC presence with SFDA authorization while focusing on complex therapies in oncology and critical care that offer higher clinical value and stronger demand in regulated healthcare markets.
Plerixafor is a hematopoietic stem cell mobilizer used along with granulocyte-colony stimulating factor (G-CSF) to mobilize stem cells into peripheral blood for collection and autologous transplantation. The therapy is widely used in haemato-oncology, particularly in patients suffering from multiple myeloma and non-Hodgkin lymphoma who are undergoing stem cell transplant procedures.
According to the company, Saudi Arabia was selected as the launch market due to its rapidly expanding oncology and transplant care infrastructure. The Kingdom currently represents the largest pharmaceutical market in the GCC region and continues to witness rising investments in advanced healthcare services under Vision 2030.
Saransh Chaudhary, President, Global Critical Care at Venus Remedies and CEO of Venus Medicine Research Centre, said the approval aligns with the company’s broader global strategy focused on differentiated specialty injectables.
“This is our first Plerixafor approval anywhere in the world, and Saudi Arabia is the right market to launch it in. The Kingdom has the largest pharmaceutical market in the GCC and one of the fastest-growing oncology and transplant infrastructures in the region,” he said.
Also Read: The Evolving Role of India as a Talent Hub for Healthcare R&D
He further added that therapies such as Plerixafor are central to the company’s evolving international portfolio because clinical complexity and stringent regulatory requirements create sustainable demand for specialty products.
The approval also comes at a time when stem cell transplantation procedures are increasing across Saudi Arabia. As more healthcare institutions adopt advanced haemato-oncology treatment protocols, demand for stem cell mobilization therapies is expected to rise steadily.
Industry estimates suggest that the Saudi Arabian pharmaceutical market is projected to grow from USD 12.1 billion in 2026 to USD 17.1 billion by 2033, registering a CAGR of 5 percent. Growth is being driven by increasing chronic disease prevalence, healthcare modernization, and government-backed healthcare reforms. At the same time, the GCC stem cell therapy market was estimated at USD 1.2 billion in 2024, with Saudi Arabia, the UAE, and Qatar emerging as the leading regional markets.
The SFDA approval will allow Venus Remedies to commercialize Plerixafor 24mg/1.2ml in Saudi Arabia through its established international distribution network. The company plans to focus primarily on tertiary oncology and transplant centers where demand for advanced injectable segment continues to increase.
Aditi K Chaudhary, President, International Business at Venus Remedies, said Saudi Arabia remains the most strategically important market in the GCC for specialty oncology therapies.
She noted that the approval gives the company a direct commercial platform in the Kingdom and will support future launches of specialty products across the region. According to her, regulatory approvals and commercial expansion go hand in hand in highly regulated markets like Saudi Arabia.
The company believes the SFDA authorization further reinforces India’s growing reputation as a reliable supplier of complex injectable products for advanced healthcare systems globally. It also reflects the increasing acceptance of Indian pharmaceutical manufacturers in regulated international markets that demand strict compliance and product quality standards.
With oncology and transplant care expected to expand further across the Middle East, Venus Remedies is positioning itself to capture opportunities in high-value specialty therapies while strengthening long-term partnerships with hospitals and healthcare providers in the GCC region.
Venus Remedies is an India-based pharmaceutical company focused on injectable formulations, oncology, critical care, and anti-infective segment. The company has a presence in more than 70 countries and operates manufacturing facilities compliant with global regulatory standards.
The company is also known for its research-driven approach through the Venus Medicine Research Centre, which focuses on developing advanced pharmaceutical formulations and specialty therapies for regulated international markets.
.jpg)
